Building Smarter Cell Therapies With AI And Synthetic Biology

Cell therapy development is entering a phase where complexity can no longer be managed by intuition alone. In this Cell & Gene Live, Cell & Gene’s Chief Editor, Erin Harris, was joined by Timothy Lu, M.D., Ph.D, Co-Founder and CEO of Senti Biosciences and Claire Aldridge, Ph.D., Board of Directors/Scientific Advisor, and together they explored how AI and synthetic biology are being applied to engineer more precise, controllable, and scalable cell therapies. The conversation examined the real advantages and limitations of using AI in complex CGT modalities. They highlighted the technologies that are generating the most excitement today and discussed how these approaches are beginning to shift development, manufacturing, and clinical strategy.